首页> 美国卫生研究院文献>Springer Open Choice >Urocortin and corticotropin-releasing factor receptor 2 in human renal cell carcinoma: disruption of an endogenous inhibitor of angiogenesis and proliferation
【2h】

Urocortin and corticotropin-releasing factor receptor 2 in human renal cell carcinoma: disruption of an endogenous inhibitor of angiogenesis and proliferation

机译:人肾细胞癌中的Urocortin和促肾上腺皮质激素释放因子受体2:内源性血管生成和增殖抑制剂的破坏

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

PurposeUrocortin (Ucn) exerts its actions through activation of two corticotropin-releasing factor receptors (CRFRs), CRFR1 and CRFR2. Involvement of Ucn/CRFR2 system in pathophysiological conditions such as the regulation of angiogenesis and inhibition of proliferation has been already reported. Suppression of neovascularization through reduction of vascular endothelial growth factor and inhibition of tumor cell cycling is modulated mainly through activation of CRFR2. To find out a possible involvement of Ucn/CRFR2 in kidney tumor, we examined the expression of Ucn and CRFR2 in normal and tumoral kidney specimens.
机译:目的泌尿激素(Ucn)通过激活两个促肾上腺皮质激素释放因子受体(CRFRs)CRFR1和CRFR2发挥作用。已经报道了Ucn / CRFR2系统参与病理生理状况,例如调节血管生成和抑制增殖。通过减少血管内皮生长因子和抑制肿瘤细胞周期来抑制新血管形成主要通过激活CRFR2来调节。为了发现Ucn / CRFR2可能参与肾脏肿瘤,我们检查了正常和肿瘤肾脏标本中Ucn和CRFR2的表达。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号